CME: Rosita Visit 1 - Metabolic Syndrome

 
Topic:
  Cardiology
Relevant Terms:
  cardiology, diabetes, endocrinology, nephrology, ophthalmology, risk reduction
Primary Audience:
   Primary Care Physicians, Cardiologists, Endocrinologists
Launch Date:
  12-Sep-08
Credits:
  0.5 AMA PRA Category 1 Credit(s)™
Expiration Date:
   30-Sep-09
Faculty:
   Course Chair: Frank M. Sacks, MD
Consultant: Michel P. Hermans, MD
Consultant: Melinda D. Maryniuk, MEd, RD, CDE
Registration:
   Register | View Additional Information

LEARNING OBJECTIVES

Upon successful completion of this activity,
the clinician will be better able to:

  1. List the criteria used for diagnosing metabolic syndrome
  2. List the most current guidelines and describe the available diagnostic tools used to assess metabolic syndrome risk factors
  3. Develop a systematic risk factor reduction plan for patients with diabetes, hypertension, dyslipidemia and other metabolic syndrome criteria
  4. Apply various therapies to treat metabolic syndrome and reduce risk factors in the context of primary and secondary prevention


Deadline:

 

December 31, 2008
Purpose:
  To promote new talents and research themes in the field of metabolic syndrome, the Metabolic Syndrome Institute (MSI) intends to stimulate experimental and clinical research in the field of metabolic syndrome by granting three annual awards – The MSI Awards for Metabolic Syndrome Research – to scientists or clinicians who will have submitted the best scientific applications according to the MSI Award Jury.
Eligibility:
  The MSI Awards will be granted to young scientists or clinicians working in the field of metabolic syndrome, insulin resistance, and/or related cardiovascular risk assessment and prevention
Awards:
   For the year 2008, three successful applicants will be granted US $10,000 each or the equivalent in euros.
Application File:
  Download Application (PDF)
Rules & Regulations:
  Download Rules & Regulations (PDF)


EPIDEMIOLOGY
  • Central obesity shown to precede other metabolic syndrome components
    (Posted: 11/28 | View Article)
  • Large increase in obesity among hypertensive patients in the United States
    (Posted: 11/14 | View Article)
  • Differences in the relative contributions of body fat content and distribution to individual components of the metabolic syndrome
    (Posted: 11/05 | View Article)
 
PATHOPHYSIOLOGICAL EFFECTS
  • Metabolic syndrome as an independent risk factor of liver cirrhosis in patients with chronic hepatitis B
    (Posted: 11/26 | View Article)
  • PCOS associated with increased incidence of glucose intolerance and increased PAI-1 in overweight and obese adolescents
    (Posted: 11/17 | View Article)
  • ApoA5 genetic variants as robust genetic biomarkers of various clinical hyperlipoproteinaemia phenotypes linked by hypertriglyceridaemia
    (Posted: 11/12 | View Article)
  • Lower fat oxidation in black girls during puberty as a potential risk factor predisposing to obesity
    (Posted: 11/11 | View Article)
  • High concentrations of small dense low-density lipoprotein as highly specific markers of familial combined hyperlipidaemia
    (Posted: 11/04 | View Article)
  • Sleep-disordered breathing in adolescents with metabolic syndrome associated with increased sympathetic nervous system activity and leptin levels
    (Posted: 11/03 | View Article)
 
METABOLIC SYNDROME COMPONENTS / RISK FACTORS /
ASSOCIATED RISKS


HIGH BLOOD PRESSURE

  • Strong association between metabolic syndrome and multiple organ damage in essential hypertension
    (Posted: 11/27 | View Article)
  • Metabolic syndrome shown to have no effect on wave reflections except when using WHO criteria
    (Posted: 11/18 | View Article)

HYPERTRIGLYCERIDEMIA

  • Hypertriglyceridaemia among smokers may be accounted for by mechanisms other than inflammation and insulin resistance
    (Posted: 11/21 | View Article)

LOW HDL-CHOLESTEROL LEVELS

  • Low high-density lipoprotein cholesterol levels in non-ST-segment elevation acute coronary syndromes
    (Posted: 11/24 | View Article)
  • Low HDL cholesterol as a marker of increased breast cancer risk in premenopausal women
    (Posted: 11/06 | View Article)
 
PROGNOSIS / OUTCOMES


CARDIOVASCULAR DISEASE

  • Fasting hyperinsulinaemia as a stronger cardiovascular risk factor in women than men
    (Posted: 11/25 | View Article)
  • Metabolic syndrome more strongly related to risk of atherosclerosis in the cerebrovascular than the peripheral circulation
    (Posted: 11/19 | View Article)
  • Gender differences in regulation of the sympathetic nervous system may contribute to gender differences in cardiovascular risk
    (Posted: 11/10 | View Article)
  • Excess adiposity shown to be strongly related to first non-ST-segment elevation myocardial infarction
    (Posted: 11/07 | View Article)


3rd International Congress on Prediabetes and Metabolic Syndrome
Date:
 April 1-4, 2009
Location:
 Nice, France
Website:
 http://www2.kenes.com
 
XV International Symposium on Atherosclerosis
Date:
 June 14-18, 2009
Location:
 Boston, MA, USA
Website:
 http://www.isa2009.org/


212 Avenue Paul Doumer
92500 Rueil-Malmaison Cedex
FRANCE
Phone: (33) 1 41 42 20 35
Fax: (33) 1 41 42 20 01
Email:
contact@metabolic-syndrome-institute.org
Website:
http://www.metabolic- syndrome-institute.org

 

2008 LANDMARK STUDIES

Hypoglycaemic Agents
Dream, Accord, Advance, Periscope

Lifestyle and Obesity Management
Stradivarius

Others
WAFACS

Antihypertensive Agents
Hyvet, OnTarget, Dream

Lipid Modifying Agents
Illuminate, Corona, Field, Meteor, Radiance 2, Illustrate

2008 ONGOING TRIALS

Hypoglycaemic Agents
Heart2D, AdRem, STARR

Lifestyle and Obesity Management
GOSPEL

Others
BEAUTIFUL

Antihypertensive Agents
VALISH, AdRem, STARR

Lipid Modifying Agents
AURORA, GISSI-HF, SEARCH, SEAS


Framingham Risk Assessment Tool
Estimates 10-year risk of developing hard CHD
> View Tool

Procam Risk Calculator
Estimates your risk of a heart attack (myocardial infarction) within the next 10 years based upon data of the PROCAM Study
> View Calculator

SCORE
(European High Risk Chart)
Estimates 10 year risk of fatal CVD in high risk regions of Europe by gender, age, systolic blood pressure, total cholesterol and smoking status.
> View Chart

UKPDS Risk Engine
The UKPDS Risk Engine is a type 2 diabetes specific risk calculator based on 53,000 patients years of data from the UK Prospective Diabetes Study, which also provides an approximate 'margin of error' for each estimate.
> View Risk Engine


Mission of the Metabolic
Syndrome Institute

Created in 2003, the Metabolic Syndrome Institute is an independent and not for profit association. Its members are international experts in lipid metabolism, diabetes, heart disease, endocrinology obesity, genetics, epidemiology, basic research and health economics. Being the first association totally devoted to the dissemination of knowledge about the metabolic syndrome, the Metabolic Syndrome Institute will provide an international multidisciplinary approach to a worldwide public health problem.

 
 
Coordinated by Dr. Scott Grundy, Past-President of the IAS